3 Year return

15.32%
20222022Jul '22Jul '2220232023Jul '23Jul '2320242024
Launched on January 2013 (12 years)

Investment Details

₹100

Minimum SIP Amount

₹5000

Minimum one time investment

Fund has no lock-in period

Calculate Returns

Based on past performance of this fund

ENTER AMOUNT

Your Investment ₹3,600
Gain
  • 27.56%
  • ₹992
  • Total Value
  • ₹4,592

Risk Involved

scale

Your principal will be at

Very High Risk

Scheme Information

Asset Under Management

₹7132.82 Cr.

Expense Ratio

0.92% (inclusive of GST)

Exit Load

1% if redeemed or switchd out on or efore completion of 1 Months from the date of allotment of units. NIl if redeemed or switched out after the completion of 1 Months from the date of allotment of units.

Ratings

ARQ Rating
0

Ratings by other agencies

0
0
0

Tax Implications

Withdrawal within 1 year

Exit load + 15% tax on gains

Withdrawal after 1 year

10% tax on gains over ₹1 Lakh per financial year

Fund Holdings

Holdings

Nippon India Mutual Fund Managers

SB

Sailesh Raj Bhan

Fund Manager since May 2018

View Details

Fund House Details

Nippon India Mutual Fund

Nippon India Mutual Fund Asset management company

AUM ₹433,896.92 Cr.
No. of Schemes 293
Setup Date June 1995

Peer Comparison

Comparison with other similar funds

Schemes by Nippon India Mutual Fund

List of mutual fund schemes by AMC

About Nippon India Pharma Fund Direct Plan IDCW Reinvestment

The Nippon India Pharma Fund Direct Plan IDCW Reinvestment is offered by Nippon Life India Asset Management Limited. The fund falls under the category of Sectoral/Thematic Funds. As a sectoral fund, it focuses on investing primarily in companies within the pharmaceutical sector. The reinvestment option allows the fund to reinvest the dividends earned to enhance the overall performance of the fund in the long run. This is an open-ended fund that allows investors to buy and sell units on any business day. The fund’s expense ratio is slightly higher than the category average.

Investment Objective of the Scheme

The main investment objective of the Nippon India Pharma Fund Direct Plan IDCW Reinvestment is to generate capital appreciation over the long term by predominantly investing in companies operating in the pharmaceutical sector. The fund aims to capitalise on growth opportunities within this specific sector.

Key Features of The Fund

5-year return 25.54%
Expense Ratio 0.92%
Fund Manager Sailesh Raj Bhan
Fund Size ₹7132.82 Cr
Risk Profile Very High

Is This Scheme Right for Me?

This fund might be suitable for investors who are bullish on the pharmaceutical sector and are looking for long-term capital growth. Since the fund predominantly invests in the pharma sector, investors should be prepared to take on higher risks. Before making an investment decision, interested investors should assess their own risk tolerance and returns expectation. Having a clear understanding of the pharma sector's dynamics is also essential.

AMC Contact Details

Name Nippon India Mutual Fund
Launch Date June 1995
Addresss Nippon Life India Asset Management Limited, 4th Floor, Tower A, Peninsula Business Park, Ganapatrao Kadam Marg, Lower Parel (W), Mumbai – 400 013
Contact 1860 266 0111
Email customercare@nipponindiaim.in
Website https://mf.nipponindiaim.com/

Disclaimer: Mutual funds are subject to market risk. Read all scheme-related documents carefully to make informed-decision.

Combat Inflation with SIP Investments

Compound growth and steady contributions through SIPs balance the negative effects of inflation, guaranteeing that your money increases faster than inflation. Use Angel One's free SIP calculator online to estimate potential returns and plan your inflation-hedging investment strategy effectively.

FAQs

What is today's NAV of Nippon India Pharma Fund Direct Plan IDCW Reinvestment?

NAV, or Net Asset Value, is the price of a single unit of a mutual fund. It is calculated by dividing the current value of holdings held by the mutual fund scheme at the end of the day by the total number of units issued. The NAV changes every day. The NAV of Nippon India Pharma Fund Direct Plan IDCW Reinvestment on May 29 2024, is ₹154.4884